Hypothesis

Circulating soluble Bcl‑2 family protein isoforms (Bcl‑2, Bcl‑xL, MCL‑1) packaged in extracellular vesicles act as molecular decoys that sequester navitoclax, reducing its free intracellular concentration and thereby predicting resistance to Bcl‑2‑targeted senolytics. In contrast, dasatinib‑quercetin (D+Q) induces senescent cell death primarily through ROS generation and SRC family inhibition, mechanisms that are not impeded by vesicle‑bound Bcl‑2 proteins. Therefore, baseline plasma levels of vesicle‑associated Bcl‑2 isoforms will inversely correlate with navitoclax‑mediated senescent cell clearance and positively correlate with D+Q efficacy.

It's plausible that EV‑bound Bcl‑2 proteins act as sinks for navitoclax.

Mechanistic Rationale

1. Extracellular vesicle (EV) secretion – Senescent cells release EVs enriched in Bcl‑2 family proteins as part of the SASP (1). These EVs can travel systemically and be taken up by neighboring or distant cells.
2. Decoy effect – Navitoclax binds Bcl‑2/Bcl‑xL with high affinity; when these proteins are present in the extracellular milieu within EVs, they compete with intracellular targets for the drug, lowering the amount of free navitoclax available to induce apoptosis (2).
3. D+Q independence – Dasatinib inhibits SRC kinases; quercetin is a flavonoid that generates oxidative stress. Neither mechanism relies on Bcl‑2 family binding, so EV‑bound Bcl‑2 proteins do not attenuate D+Q activity (3).
4. Biomarker feasibility – Quantitative ELISA or mass‑spec assays can measure vesicle‑associated Bcl‑2 isoforms in plasma prior to treatment, enabling patient stratification.

Testable Predictions

• Prediction 1: Patients with high baseline plasma EV‑Bcl‑2/xL levels will show <30% reduction in tissue p16^INK4a^ signal after standard navitoclax dosing, whereas those with low levels will achieve >60% clearance.
• Prediction 2: The same high‑EV‑Bcl‑2/xL cohort will exhibit ≥50% reduction in p16^INK4a^ after a comparable D+Q regimen, demonstrating a reciprocal relationship.
• Prediction 3: In vitro, adding purified senescent‑cell‑derived EVs to navitoclax‑treated cultures will increase the EC50 for apoptosis in a dose‑dependent manner, while EC50 for D+Q remains unchanged.

Experimental Design

• Enroll 60 older adults with mild NAFLD or idiopathic pulmonary fibrosis (conditions with documented senescent cell burden).
• Collect baseline plasma, isolate EVs via ultracentrifugation, quantify Bcl‑2, Bcl‑xL, MCL‑1 by ELISA.
• Randomize to navitoclax (1 mg/kg weekly × 3 doses) or D+Q (dasatinib 100 mg + quercetin 1000 mg PO daily for 3 consecutive days) in a crossover design with washout.
• Pre‑ and post‑treatment biopsies (liver or lung) assessed for p16^INK4a^ and SA‑β‑gal; circulating SASP factors (IL‑6, IL‑8) measured as pharmacodynamic readouts.
• Statistical analysis: linear regression of baseline EV‑Bcl‑2/xL levels versus percent change in p16^INK4a^; interaction term to test differential drug effect.

Potential Impact

If validated, this biomarker‑driven approach would enable precision senolytic therapy, sparing patients unlikely to benefit from navitoclax while directing them to D+Q or vice‑versa, thereby improving efficacy and reducing toxicity (e.g., navitoclax‑induced thrombocytopenia). It also provides a mechanistic explanation for the observed tissue‑selectivity limits of Bcl‑2 inhibitors and rationalizes combination strategies that target EV release (e.g., GW4869) to enhance navitoclax bioavailability.